Assessing Inhibikase Therapeutics Financial Health and Future Prospects
November 14, 2023 marks an important date for Inhibikase Therapeutics (NASDAQ:IKT) as they are set to unveil their latest quarterly ...
Tag: IKT
Inhibikase Therapeutics Unveils Analysis of Risvodetinib IkT148009 in Parkinsons Disease Treatment
On October 16, 2023, Inhibikase Therapeutics unveiled an analysis of eleven participants from the 201 trial, shedding light on the ...
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib A Milestone in Rare Disease Treatment
In a significant development on October 4, 2023, Inhibikase Therapeutics achieved a major milestone as it was granted the highly ...
Inhibikase Therapeutics Revolutionizing Parkinsons Treatment with Groundbreaking Formulation
On August 24, 2023, Inhibikase Therapeutics made an exciting announcement regarding their groundbreaking development in the pharmaceutical industry. They have ...
Inhibikase Therapeutics Pioneering Advances in Parkinsons Research and Development
On August 22, 2023, Inhibikase Therapeutics made an exciting announcement regarding their participation in the upcoming International Congress of Parkinson's ...
Analyst Expresses Confidence in Inhibikase Therapeutics with Increased Price Target
On August 15, 2023, Edward White, an analyst at HC Wainwright & Co., expressed his confidence in Inhibikase Therapeutics (NASDAQ:IKT) ...
Inhibikase Therapeutics Announces Reverse Stock Split to Comply with Nasdaq Requirements
Inhibikase Therapeutics, a cutting-edge pharmaceutical company in the clinical stage of developing protein kinase inhibitor therapeutics for the treatment of ...
Analyst Reiterates Buy Rating and Price Target for Inhibikase Therapeutics
Edward White, an analyst from HC Wainwright & Co., has recently reiterated his Buy rating on Inhibikase Therapeutics (NASDAQ:IKT) and ...
Inhibikase Therapeutics Announces Progress in Phase 2 Clinical Trial for Parkinsons Disease Treatment
On May 16, 2023, Inhibikase Therapeutics made an exciting announcement about the progress of their Phase 2 '201' clinical trial ...